The present invention is concerned with methods and compositions useful for the treatment or prevention of skin conditions or skin disease including, for example, pruritis and atopic dermatitis. In certain aspects, the methods and compositions described herein target MR1-restricted T cells, and in particular classical mucosal-associated invariant T (MAIT) cells, by administering non-agonistic MR1 ligands in both prophylactic and therapeutic regimes as a means to target the disease pathology of atopic dermatitis. The non-agonistic MR1 ligands described herein include, without limitation, 6-formylpterin (6FP), acetyl-6-formylpterin (Ac6FP), 3-formylsalicylic acid (FSA), luteolin, genistein, 5-amino-6-(2-deoxy)-D-ribitylaminouracil (5-A-(2-deoxy)RU) and 5-(2-oxopropylideneamino)-6-(2-deoxy)-D-ribitylaminouracil (5-OP-(2-deoxy)RU) as well as combinations thereof, and in certain examples, may be formulated as topical compositions for administration to a patient requiring treatment. In other aspects, the compositions described herein may be administered in conjunction with UV light, in particular UVB light, as a combination treatment to target MR1-restricted T cells, including MAIT cells.La présente invention concerne des procédés et des compositions utiles pour le traitement ou la prévention d'affections cutanées ou d'une maladie cutanée comprenant, par exemple, le prurit et la dermatite atopique. Dans certains aspects, les procédés et les compositions de l'invention ciblent des lymphocytes T restreints par MR1 et, en particulier, des lymphocytes T invariants associés aux muqueuses (MAIT - mucosal-associated invariant T) classiques par administration de ligands MR1 non agonistes à la fois dans des régimes prophylactiques et thérapeutiques en tant que moyen pour cibler la pathologie de la dermatite atopique. Les ligands MR1 non agonistes décrits dans la description comprennent, sans limitation, la 6-formylptérine (6 FP), l'acétyl-6-formylptérine (Ac6FP), l'acide 3-formyls
